VIP vs Humanin
Both VIP and Humanin are used for neuroprotection. Here's how their evidence, dosing, and regulatory status actually compare.
VIP
Evidence BVasoactive Intestinal Peptide
A 28-amino-acid neuropeptide with broad immunomodulatory effects. Used clinically (intranasal) by some practitioners for chronic inflammatory response syndrome (CIRS).
View full VIP profile →Humanin
Evidence BHumanin (HN)
A 24-amino-acid mitochondrial-derived peptide with cytoprotective effects across Alzheimer's, diabetes, and atherosclerosis preclinical models. Endogenous levels decline sharply with age.
View full Humanin profile →Side-by-Side
| Attribute | VIP | Humanin |
|---|---|---|
| Evidence Grade | B | B |
| FDA Status | Not FDA-approved — investigational; ongoing trials for sarcoidosis | Not FDA-approved — mitochondrial-derived peptide research compound |
| Typical Dose | 50 mcg intranasal, 4 times daily (CIRS protocols) | Research range: 0.5–1 mg subcutaneous (rare clinical use) |
| Clinics Indexed | 24 | 5 |
| Categories | anti-inflammatory, neuroprotection | mitochondrial, longevity, neuroprotection |
Key reported benefits — VIP
- ✓Anti-inflammation
- ✓Pulmonary effects
- ✓Neuroprotection
Key reported benefits — Humanin
- ✓Cytoprotection
- ✓Anti-amyloid effects
- ✓Insulin sensitization
Educational use only
This comparison is for educational purposes and not medical advice. Peptide selection should be made with a licensed medical professional based on your individual goals, health history, and current evidence quality.